{"id":169930,"date":"2025-08-08T05:26:50","date_gmt":"2025-08-08T09:26:50","guid":{"rendered":"https:\/\/44.250.171.167\/?p=169930"},"modified":"2025-08-11T01:27:44","modified_gmt":"2025-08-11T05:27:44","slug":"alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy\/","title":{"rendered":"Alembic Pharmaceuticals Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&amp;D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/cefcecec-aceb-453e-85f8-e1b83fd2b5de.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> Earnings Results<\/p>\n<h2>Q1 FY26 Earnings Results<\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b91,711 crore, up 9.54% year-on-year (YoY) from \u20b91,562 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b91,528 crore, up 8.6% YoY from \u20b91,407 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9154 crore, up 14.07% from \u20b9135 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b97.85, up 14.60% from \u20b96.85 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Healthy Revenue Growth:<\/strong> The 10% increase in revenue reflects strong sales performance in both domestic and international markets, driven by demand for key formulations and APIs.<\/li>\n<li><strong>Effective Cost Management:<\/strong> Total expenses rose at a slower pace than revenue, highlighting cost discipline and operational efficiencies across manufacturing and R&amp;D activities.<\/li>\n<li><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/cefcecec-aceb-453e-85f8-e1b83fd2b5de.pdf\" target=\"_blank\" rel=\"noopener\">Profitability Expansion:<\/a> Net profit and EPS rose over 14%, outpacing revenue growth, which indicates margin expansion and better product mix or operational leverage.<\/li>\n<li><strong>Innovation &amp; Exports:<\/strong> Alembic continues to benefit from sustained investments in R&amp;D, resulting in robust product pipelines, new launches, and regulatory approvals across multiple geographies.<\/li>\n<li><strong>Business Focus:<\/strong> The diversified product portfolio, with a presence in chronic and acute therapies, supports defensive revenue streams and future growth aspirations.<\/li>\n<li><strong>Strategic Initiatives:<\/strong> Continued focus on expanding international footprints, optimizing supply chains, and launching high-value products remains central to Alembic&#8217;s strategy.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in <\/strong>Q1 FY26 Earnings<\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/cefcecec-aceb-453e-85f8-e1b83fd2b5de.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> was a solid quarter for Alembic Pharmaceuticals, marked by double-digit profit growth, strong revenue momentum, and effective expense management. The company&#8217;s emphasis on R&amp;D-led innovation and global expansion continues to drive its operational strength.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-169931\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png\" alt=\"APLLTD Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>Alembic Pharmaceuticals is poised to leverage growth opportunities with new product launches, continued investments in R&amp;D, and further expansion in key export markets. Focus on operational efficiency, pipeline enhancement, and regulatory compliance is expected to support sustained profitability and value creation through FY26 and beyond.<\/p>\n<p>To view Alembic Pharmaceuticals &#8216;s previous results: <a href=\"https:\/\/44.250.171.167\/symbol\/alembicltd\/\">Click Here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&amp;D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its Q1 FY26 Earnings Results Q1 FY26 Earnings [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":169931,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-169930","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170558,"url":"https:\/\/alphastreet.com\/india\/alembic-q1-fy26-earnings-results\/","url_meta":{"origin":169930,"position":0},"title":"Alembic Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alembic Ltd, established in 1907, operates in the pharmaceuticals, real estate, and power assets sectors. It is the flagship company of the Alembic Group and holds significant stakes in Alembic Pharma Ltd and Paushak Limited. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b950 crore, down\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALEMBICLTD Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/alembic.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/alembic.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/alembic.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/alembic.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/alembic.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/alembic.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":169930,"position":1},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":147370,"url":"https:\/\/alphastreet.com\/india\/earnings-alembic-pharmaceuticals-limited-nse-aplltd-q4fy23-results-out-total-income-fell-1-yoy\/","url_meta":{"origin":169930,"position":2},"title":"Earnings | Alembic Pharmaceuticals Limited (NSE: APLLTD): Q4FY23 Results Out; Total Income fell 1% YoY.","author":"Divyansh_Kasana","date":"May 26, 2023","format":false,"excerpt":"Alembic Pharmaceuticals is a leading player in the pharmaceutical industry, specializing in the development, manufacturing, and marketing of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). The company boasts three research and development (R&D) facilities dedicated to innovative drug development and technological advancements. With a strong focus on quality\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-1-8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-1-8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-1-8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-1-8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-1-8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-1-8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145171,"url":"https:\/\/alphastreet.com\/india\/earnings-alembic-pharmaceuticals-limited-nse-aplltd-q4fy23-results-out-total-income-fell-1-3-yoy\/","url_meta":{"origin":169930,"position":3},"title":"Earnings | ALEMBIC PHARMACEUTICALS LIMITED (NSE: APLLTD): Q4FY23 Results Out; Total Income fell 1.3% YoY.","author":"Divyansh_Kasana","date":"May 5, 2023","format":false,"excerpt":"Alembic Pharmaceuticals is an Indian pharmaceutical company that specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including formulations and active pharmaceutical ingredients. Founded in 1907, the company has a strong focus on research and development, and has invested heavily in state-of-the-art facilities and advanced\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-22.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-22.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-22.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-22.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-22.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/4b0b185d-fd09-4e7e-947d-ef141089055f-22.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170458,"url":"https:\/\/alphastreet.com\/india\/aarti-pharmalabs-q1-fy26-earnings-results\/","url_meta":{"origin":169930,"position":4},"title":"Aarti Pharmalabs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Pharmalabs Ltd, incorporated in 2019, is a manufacturer of pharmaceuticals and nutraceuticals. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9386 crore, down 30.45% year-on-year (YoY) from \u20b9555 crore in Q1 FY25. Total Expenses: \u20b9323 crore, down 33.26% YoY from \u20b9484 crore. Consolidated Net\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIPAHRM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APHARM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169622,"url":"https:\/\/alphastreet.com\/india\/sun-pharmaceutical-industries-ltd-q1-fy26-earnings-results-20-fall-in-profits\/","url_meta":{"origin":169930,"position":5},"title":"Sun Pharmaceutical Industries Ltd Q1 FY26 Earnings Results &#8211; 20% fall in Profits","author":"Chirag Gupta","date":"July 31, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/6-5.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=169930"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/169930\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/169931"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=169930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=169930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=169930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}